Do COVID-19 infection among patients increase the risk of Alzheimer’s disease?

Document Type : Letter to the Editor

Authors

1 Department of Science, School of Science and Technology, The Open University of Hong Kong, Ho Man Tin, Kowloon, Hong Kong

2 School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong

3 Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China

Abstract

The COVID-19 outbreak has occurred for more than ten months. Some COVID-19 complications are still unknown. Is there any long-term effect on the neurologic manifestations after COVID-19? Will the infected patient get a greater risk of Alzheimer’s disease? May the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have a long latency period in the Central Nervous System (CNS)? If this is possible, it has various non-specific inflammatory diseases that initiate and re-activate certain inflammatory or oxidative reactions in Alzheimer’s disease, but the neurological complications of COVID-19 are limited to individual cases or small case series according to several published papers.
Recently, Varatharaj et al. reported the neurological and neuropsychiatric complications of COVID-19 in 153 patients who were divided into two groups, cerebrovascular and neuropsychiatric. 96% of patients with cerebrovascular events are also altered with mental status in the age range from 71 to 80. The results showed 43% of patients with neuropsychiatric disorders would have a new-onset psychosis such as neurocognitive, dementia, and Alzheimer’s disease. (To be continued)...

Keywords

Main Subjects

Files

Share

How to cite

Statistics